Pharmac Indicates Interest In Funding Cancer Treatment Bevacizumab

“Today, we have issued a Future Procurement Opportunity (FPO) for the cancer treatment bevacizumab,” says Pharmac’s Chief Medical Officer, Dr David Hughes.